TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Ten-Eleven-Translocation 2 (TET2) gene mutations are observed in various myeloid neoplasms.
• The clinical significance and timing of TET2 mutations in cytogenetically normal acute myeloid leukemia (CN-AML) are not well understood.
• Understanding mutation order is crucial for elucidating leukemogenesis.

Purpose of the Study:

• To determine the frequency and clinical relevance of TET2 mutations in CN-AML.
• To investigate the timing of TET2 mutations relative to other common mutations in CN-AML.
• To analyze the association of TET2 mutations with other molecular markers and patient outcomes.

Main Methods:

• Direct sequencing of the TET2 coding region in 215 CN-AML patients.
• Analysis of associations with other molecular markers (CEBPA, DNMT3A, NPM1, FLT3, IDH1/2, RAS, WT1, MLL-PTD).
• Targeted deep resequencing and progenitor-derived colony assays in a subset of patients to determine mutation order.

Main Results:

• TET2 mutations were identified in 6% (13/215) of CN-AML patients.
• TET2 mutations were associated with older age and higher platelet counts.
• TET2 mutations frequently co-occurred with NPM1 and DNMT3A mutations, were mutually exclusive with MLL-PTD and IDH1/2 mutations, and appeared later than NPM1 and DNMT3A mutations during disease progression.

Conclusions:

• TET2 mutations represent subclones in CN-AML, acquired later in leukemogenesis.
• TET2 mutation status does not significantly affect overall or relapse-free survival in CN-AML.
• The findings provide insights into the stepwise acquisition of mutations in CN-AML development.